Provectus Biopharmaceuticals, Inc. (PVCT)
OTCMKTS · Delayed Price · Currency is USD
0.0600
-0.0020 (-3.23%)
Jul 27, 2026, 3:22 PM EST
PVCT Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 0.22 | 0.25 | 0.31 | 0.08 | 0.02 | 0.68 |
Cash & Short-Term Investments | 0.22 | 0.25 | 0.31 | 0.08 | 0.02 | 0.68 |
Cash Growth | -42.66% | -18.26% | 301.49% | 254.44% | -96.84% | 602.43% |
Accounts Receivable | - | - | - | 0 | 0 | - |
Other Receivables | - | - | - | - | - | 0.01 |
Receivables | - | - | - | 0 | 0 | 0.01 |
Prepaid Expenses | 0.18 | 0.24 | 0.25 | 0.34 | 0.47 | 0.33 |
Restricted Cash | - | - | 0.18 | 0.95 | 1.41 | 2.42 |
Other Current Assets | 0.05 | 0.07 | 0.24 | - | - | - |
Total Current Assets | 0.46 | 0.57 | 0.98 | 1.36 | 1.9 | 3.44 |
Property, Plant & Equipment | 0.12 | 0.13 | 0.03 | 0.08 | 0.14 | 0.07 |
Total Assets | 0.58 | 0.7 | 1.01 | 1.45 | 2.04 | 3.51 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 0.82 | 0.72 | 1.11 | 1.68 | 2.09 | 1.29 |
Accrued Expenses | 3.73 | 3.31 | 2.35 | 3.39 | 2.48 | 2.02 |
Short-Term Debt | 0.16 | 0.22 | 0.21 | 0.28 | 0.24 | 0.24 |
Current Portion of Long-Term Debt | 2.49 | 2.61 | 2.95 | 2.68 | 1.83 | 1.46 |
Current Portion of Leases | 0.05 | 0.05 | 0.03 | 0.05 | 0.04 | 0.05 |
Current Unearned Revenue | - | - | 0.34 | 0.95 | 1.51 | 2.5 |
Other Current Liabilities | - | - | - | - | - | 0.15 |
Total Current Liabilities | 7.24 | 6.9 | 6.98 | 9.02 | 8.19 | 7.7 |
Long-Term Debt | - | 0.02 | - | - | - | - |
Long-Term Leases | 0.07 | 0.08 | - | 0.03 | 0.07 | - |
Total Liabilities | 7.31 | 7 | 6.98 | 9.04 | 8.27 | 7.7 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 | 0.42 |
Additional Paid-In Capital | 257.04 | 256.18 | 251.09 | 244.71 | 242.95 | 241.44 |
Retained Earnings | -264.14 | -262.85 | -257.42 | -252.69 | -249.59 | -246.03 |
Comprehensive Income & Other | -0.06 | -0.06 | -0.06 | -0.06 | -0.04 | -0.03 |
Total Common Equity | -6.74 | -6.31 | -5.97 | -7.62 | -6.25 | -4.21 |
Minority Interest | -0.01 | -0 | -0.01 | - | - | - |
Shareholders' Equity | -6.73 | -6.3 | -5.97 | -7.59 | -6.23 | -4.19 |
Total Liabilities & Equity | 0.58 | 0.7 | 1.01 | 1.45 | 2.04 | 3.51 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 2.77 | 2.98 | 3.18 | 3.03 | 2.18 | 1.74 |
Net Cash (Debt) | -2.54 | -2.73 | -2.88 | -2.95 | -2.16 | -1.06 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 | -0.00 |
Filing Date Shares Outstanding | 420.28 | 420.28 | 420.28 | 419.52 | 419.5 | 419.45 |
Total Common Shares Outstanding | 420.28 | 420.28 | 420.28 | 419.52 | 419.5 | 419.45 |
Working Capital | -6.78 | -6.33 | -6 | -7.65 | -6.29 | -4.26 |
Book Value Per Share | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
Tangible Book Value | -6.74 | -6.31 | -5.97 | -7.62 | -6.25 | -4.21 |
Tangible Book Value Per Share | -0.02 | -0.02 | -0.01 | -0.02 | -0.01 | -0.01 |
Machinery | 0.12 | - | - | 0.12 | 0.12 | 0.12 |